A comparative study of 2 new phosphate binders (sevelamer and lanthanum carbonate) in routine clinical practice.
BACKGROUND
Lack of adherence may influence the efficiency of phosphate binders. Our clinical hypothesis was that if lanthanum carbonate (LC) might offer some advantage over sevelamer (S), that that would be in those patients in whom serum phosphate (P) levels were not controlled by S or in those requiring high doses of it, presuming that therapeutic compliance with S could be inadequate. The aim of this study was to compare the cost-consequences of changing from S to LC.


METHODS
This was a prospective comparative before-after interventional study. Fifty-one hemodialysis patients prescribed a large number of tablets of S (≥ 9 tablets/day) and/or had serum phosphorus (P) levels >5.5 mg/dL were changed from S to LC; 68 patients who did not meet those criteria served as controls.


RESULTS
Mean daily number of total phosphate binder tablets was reduced after the introduction of LC (13.9 ± 5.5 at time 0 vs. 7.7 ± 4.6 at 12 months; p<0.001). LC was suspended in 14 patients (31.1%), due to a wish to return to the previous medication (S). Percentage compliance with the objectives recommended by the NFK-KDOQI guidelines improved after the change (patients with P <5.5 mg/dL: 46.9% at month 0 and 72.5% at month 12; p<0.01). The incremental cost of changing from S (month 0) to LC (month 12) was -107.8 monthly, considering only the costs of phosphate binders. LC reached the P objective at a lower cost (euro 582.2 vs. euro 1,038.5; -44%; p<0.01).


CONCLUSIONS
A complete change from S to LC in these particular kinds of patients significantly decreased the cost of treatment while also improving the achievement of NFK-KDOQI guideline objectives for mineral metabolism.
Arenas
María Dolores
MD
Department of Nephrology, Hospital Perpetuo Socorro, Plaza Dr. Gomez Ulla 15, Alicante, Spain. lola@olemiswebs.com
Rebollo
Pablo
P
Malek
Tamara
T
Moledous
Analia
A
Gil
M Teresa
MT
Alvarez-Ude
Fernando
F
Morales
Ana
A
Cotilla
Eva
E
D003362:Cost-Benefit Analysis; D017850:Economics, Pharmaceutical; D006801:Humans; D054559:Hyperphosphatemia / Q000188:drug therapy*; D007811:Lanthanum / Q000627:therapeutic use*; D010710:Phosphates / Q000097:blood; D011073:Polyamines / Q000627:therapeutic use*; D011446:Prospective Studies; D006435:Renal Dialysis; D000069603:Sevelamer
D010710:Phosphates; D011073:Polyamines; C119467:lanthanum carbonate; D007811:Lanthanum; D000069603:Sevelamer